Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of ZYPREXA and ZYPREXA VELOTAB in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ZYPREXA and ZYPREXA VELOTAB, as with all other anti-psychotics (including first generation anti-psychotics), provide a moderate Improvement in Actual Benefit (IAB III) in the treatment of schizophrenia. |
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
EjrkfBG9jnp5Phgn
